Clinical Study Results

• Sibrotuzumab - Colorectal Neoplasms

  Clinical Study Number	1152.10
  Study Indication	Colorectal Neoplasms
  Product	Sibrotuzumab
  Generic Name	Sibrotuzumab
  Lab Code
  Clinical Phase	IIa
  Study Title	A phase II uncontrolled study to evaluate the antitumour activity and safety of intravenous BIBH 1, administered in a weekly dose of 100 mg in 12 weeks, in patients with metastatic colorectal cancer.
  Study Document	Trial synopsis 1152.10_CO english

• Sibrotuzumab - Carcinoma, Non-Small-Cell Lung

  Clinical Study Number	1152.3
  Study Indication	Carcinoma, Non-Small-Cell Lung
  Product	Sibrotuzumab
  Generic Name	Sibrotuzumab
  Lab Code
  Clinical Phase	I
  Study Title	A Phase I Single Dose Escalation Study of BIBH 1 in Patients with Non-Small Cell Lung Cancer Scheduled for Resection
  Study Document	Trial synopsis 1152.3_CO english

• Sibrotuzumab - Carcinoma, Non-Small-Cell Lung

  Clinical Study Number	1152.6
  Study Indication	Carcinoma, Non-Small-Cell Lung
  Product	Sibrotuzumab
  Generic Name	Sibrotuzumab
  Lab Code
  Clinical Phase	I
  Study Title	A Phase I Single Dose Escalation Study of 131 I-Sibrotuzumab in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer
  Study Document	Trial synopsis 1152.6_CO english